Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b, Open-Label Study of the Pressure-Enabled Hepatic Artery Infusion of SD-101, a TLR9 Agonist, Alone or in Combination With Intravenous Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

NCT04935229 is registered in ClinicalTrials.gov with TriSalus Life Sciences, Inc. as lead sponsor.

NCT NCT04935229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04935229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b, Open-Label Study of the Pressure-Enabled Hepatic Artery Infusion of SD-101, a TLR9 Agonist, Alone or in Combination With Intravenous Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
Lead sponsor
TriSalus Life Sciences, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
August 2, 2021
Completion date
July 17, 2024
Enrollment
67 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic uveal melanoma in the liver